Human Papillomavirus
Aug 15, 2023
J&J’s 2-in-1 Tablet for Prostate Cancer; FDA Approves TALVEY for Heavily Pretreated Multiple Myeloma; PDS Biotech Updated on VERSATILE-003 Trial; FDA Issues CRL to NDA for Avasopasem in Radiotherapy-Induced Severe Oral Mucositis in HNC; FDA Orphan Drug Designation to Genprex’s REQORSA; FDA Orphan Drug Designation to Bloomsbury’s BGT-OTCD
FDA Clears J&J’s 2-in-1 Tablet for Prostate Cancer Johnson & Johnson's Janssen Pharmaceutical Companies stated that the US Food and Drug Administration (FDA) had approved AKEEGA (niraparib and abiraterone acetate), the first-and-only dual-action tablet combining a PARP inhibitor including abiraterone ace...
Read More...
Jan 21, 2019
Cervical cancer
Ladies, January is the month of raising awareness about cervical cancer. In the US, 250000 women are affected every year. One can refrain from the cancer by avoiding human papillomavirus, or HPV, which is sexually transmitted. We can eliminate cervical cancer as a public health problem through intensified vaccinati...
Read More...
Sep 15, 2017
Human Papillomavirus (HPV) Prophylaxis– Expected to see a steady growth from 2015-2025
A total of approximately 7.3 Million people were vaccinated with HPV vaccines in 2016, as per the latest report of DelveInsight. Human Papillomavirus is a double stranded DNA virus that infects squamous epithelia including the skin and mucosae of the upper respiratory and anogenital tracts. HPV is a group of more th...
Read More...
-Agonist.png "Toll-like Receptors Agonist")
